What is Vumerity (Bafelyan)?
Vumerity, with the active ingredient bafelyan, is a medication approved for the treatment of relapsing forms of multiple sclerosis (MS). It belongs to a class of drugs known as immunomodulators. The drug works by decreasing the number of relapses and slowing the accumulation of disability in individuals with MS [1].
How Does Vumerity Work?
Bafelyan, the active component of Vumerity, is an oral sphingosine 1-phosphate (S1P) receptor modulator. It targets specific S1P receptors in lymphocytes, which are a type of white blood cell. By binding to these receptors, bafelyan causes lymphocytes to be retained within lymph nodes, thereby reducing their presence in the central nervous system. This reduction is believed to prevent them from contributing to the inflammation and nerve damage characteristic of multiple sclerosis [1].
What Forms of MS Does Vumerity Treat?
Vumerity is indicated for individuals experiencing relapsing forms of multiple sclerosis. This includes clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis [1].
When Did Vumerity Receive FDA Approval?
The U.S. Food and Drug Administration (FDA) approved Vumerity on October 22, 2019 [1].
What Are the Potential Side Effects of Vumerity?
Common side effects associated with Vumerity include headache, nausea, diarrhea, and upper respiratory tract infection. More serious, though less frequent, side effects can occur. These may involve infections, liver enzyme elevations, and a temporary decrease in heart rate (bradycardia) upon initiation of treatment. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
How Does Vumerity Compare to Other MS Treatments?
Vumerity is one of several disease-modifying therapies available for multiple sclerosis. It functions similarly to other S1P receptor modulators like fingolimod (Gilenya) and siponimod (Mayzent) by modulating lymphocyte traffic. However, Vumerity is designed with a different metabolic profile, which may lead to distinct interactions and tolerability compared to other S1P modulators. The choice of MS treatment often depends on the individual patient's disease activity, medical history, and tolerance to specific medications [1].
When Does Vumerity's Patent Protection End?
Information regarding specific patent expiration dates for Vumerity is tracked by DrugPatentWatch.com [2]. Patent durations can be complex and may involve multiple patents covering different aspects of the drug's composition, formulation, and methods of use.
Who Manufactures Vumerity?
Vumerity is manufactured by Biogen [1].
What Clinical Trials Supported Vumerity's Approval?
The approval of Vumerity was based on data from clinical trials, including the multi-center, randomized, double-blind, active-controlled Phase 3 trial named ASCLEPIOS I and II. These trials demonstrated that Vumerity significantly reduced the annualized relapse rate and slowed the progression of disability compared to interferon beta-1a [1].
Sources
1. Biogen. (n.d.). Vumerity. Retrieved from https://www.drugpatentwatch.com/drug/vumerity
2. DrugPatentWatch.com. (n.d.). DrugPatentWatch. Retrieved from https://www.drugpatentwatch.com/